\n
![](\"https:\/\/readwrite.com\/wp-content\/uploads\/2024\/04\/Synchron-launches-patient-registry-challenging-Neuralink-in-brain-technology-900x600.png\")
<\/p>\n [ad_1]
\n<\/p>\n
Synchron Inc., a rival of Elon Musk\u2019s Neuralink<\/a> brain implant startup, has announced the launch of an online registry for patients interested in joining its trial.<\/p>\n According<\/a> to Reuters, the trial could include dozens of participants, with around 120 clinical trial centers already expressing an interest in helping to conduct the study.<\/p>\n \u201cWe are thrilled to launch our community-centered BCI (brain-computer interface) registry,\u201d said<\/a> Tom Oxley, CEO and founder, Synchron. \u201cThere is a grass roots movement happening with BCI. We are creating an avenue for potential users and their physicians to engage and stay connected while we prepare for the next stage of clinical trials.\u201d<\/p>\n We\u2019re excited to announce the launch of our community-centered BCI registry to bring patients, carers and clinicians together to learn how #BCI<\/a> is being designed to provide benefit to people with limited mobility. \ud83e\udde0\ud83e\udde0 https:\/\/t.co\/9dxb6d7NfR<\/a><\/p>\n \u2014 Synchron (@synchroninc) April 8, 2024<\/a><\/p>\n<\/blockquote>\n Based in New York, Synchron has reportedly made more progress in testing its brain implant technology than Neuralink. Both firms are focused on enabling paralyzed patients to type on computers by using devices that decode brain signals.<\/p>\n Synchron was granted authorization by the U.S. for preliminary testing in July 2021 and has since implanted its device in six patients. The company reports that earlier trials involving four patients in Australia revealed no serious adverse side effects.<\/p>\n The neurotechnology company is in the process of analyzing U.S. data to gear up for a more extensive study and is currently waiting for approval from the U.S. Food and Drug Administration to move forward, Oxley said.<\/p>\n In January, Musk reached a major milestone by successfully implanting its first human patient<\/a> with a wireless brain-computer interface chip. The embedded device has reportedly already detected \u201cpromising neuron spikes\u201d from the patient. It was then said the patient managed to move a computer mouse<\/a> \u201cby just thinking\u201d, and then played an online chess game<\/a>.<\/p>\n Synchron, backed by billionaire investors Jeff Bezos and Bill Gates, competes with Neuralink in the specialized field of brain-computer interface (BCI) devices. These devices, which either penetrate the brain or rest on its surface, provide direct communication with computers through electrodes. To date, no company has secured final FDA approval to sell a BCI brain implant.<\/p>\n The device is placed inside a blood vessel on the brain\u2019s surface through a simple procedure using the jugular vein. Once in place, it senses the brain\u2019s movement signals and sends them wirelessly, aiming to let severely paralyzed patients control devices like computers without using their hands, just by thinking.<\/p>\n Featured image: Canva<\/em><\/p>\n<\/p><\/div>\n\n
Who owns Synchron?<\/h2>\n